Accelerate Diagnostics — Investor Presentation (December 2023)
14 slides from Accelerate Diagnostics's investor presentation, Dec 13, 2023
Slide 1: December 2023 Company Presentation
December 2023 Company Presentation
Slide 2: Legal Disclaimer: Forward-Looking Statements
1 Legal Disclaimer Forward-Looking Statements This presentation contains, and the Company’s responses to various questions from investors may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of th
Slide 3: Executive Summary
2 Executive Summary The Accelerate Pheno® is the first rapid Antimicrobial Susceptibility Testing (AST) platform to receive FDA approval and has strong IP, thought-leading customers, and dozens of publications proving the high clinical impact from rapid diagnostic results on patient outcomes We beli
Slide 4: Existing Paradigms for Management of Bloodstream Infections are Insufficient
3 Existing Paradigms for Management of Bloodstream Infections are Insufficient Lack of rapid and innovative microbiology diagnostic tools impairs patient care and burden healthcare providers Cycle begins anew and antibiotic options become more limited Clinicians overtreat septic patients until resul
Slide 5: Accelerate's Pheno Established the Rapid AST Market
4 Accelerate’s Pheno® Established the Rapid AST Market Accelerate’s design of the first fully automated, FDA-approved, AST solution provides a foundation for future product development and commercial success Achievements in Pioneering the AST Market Introduced first fully automated, FDA-approved, ra
Slide 6: Market Learnings with the Accelerate Pheno System
5 Market Learnings with the Accelerate Pheno® System Wave™ was designed based on lessons from the launch of Pheno® and customer feedback Limited Menu: Testing only PBC samples, which is ~3-5% of lab volumes, added additional instrumentation to lab workflows Consumable Cost Justification: Launched pr
Slide 7: Wave Expands Potential Addressable Market By Offering Both PBC and Isolates
6 WaveTM Expands Potential Addressable Market By Offering Both PBC and Isolates Accelerate is positioning Wave™ to compete against peers and emerging competitors with a market differentiated solution +$800M +$1,000M +$375M +$300M Rapid PBC Susceptibility Rapid Isolate Colony ID Rapid Isolate Suscept
Slide 8: Wave is Designed to Advance Rapid Testing with a Decade of Innovation
7 Wave™ is Designed to Advance Rapid Testing with a Decade of Innovation Unlocking the next generation in antimicrobial susceptibility testing Wave™ is designed to address the entirety of the AST market • True same-shift results, improving patient outcomes • Universal Platform for multiple AST needs
Slide 9: Holographic imaging enables enhanced real-time single-cell analysis
8 + β-Lactam (filamentation) + Carbapenem (spheroplasts) Holographic imaging enables enhanced real-time single-cell analysis 3-dimensional environment with enhanced resolution Pheno® WaveTM Pheno® WaveTM Pheno® WaveTM Wave™ improves and expedites analysis of antibiotic induced morphological changes
Slide 10: Preliminary Wave GN PBC Performance
9 Preliminary WaveTM GN PBC Performance (1,2) Initial data producing quality results in less than 4.5 hours, on average Data shown for common Enterobacterales organisms: ‒ Citrobacter freundii ‒ Citrobacter koseri ‒ Enterobacter cloacae ‒ Escherichia coli ‒ Klebsiella aerogenes ‒ Klebsiella oxytoca
Slide 11: Customer Feedback on Wave
10 Customer Feedback on WaveTM ~90% of existing customers indicated interest in evaluating WaveTM Universal AST Platform Ability to run PBC & Isolates together Fastest AST Results Delivering same-shift results in less than 4.5 hrs Budget-Friendly Cost-effective pricing for PBC & Isolates Leveraging
Slide 12: Transitioning Pheno Customers to Arc + Wave Creates Powerful Economics
11 Transitioning Pheno® Customers to Arc™ + Wave™ Creates Powerful Economics (1,2,3,4) Illustration of converting existing Pheno® customers to WaveTM PBC and Isolate testing Customer Wallet-Share Highlights ▪ Initial conversion of existing Pheno® PBC customers to GN WaveTM generates an estimated mar
Slide 13: Planned Timeline of Wave Launch and Commercialization
12 4Q 2023 Final system integration, complete Development, enter Verification and Validation 2Q 2024 Start Clinical Trial European Society of Clinical Microbiology and Infectious Diseases and American Society for Microbiology data releases on WaveTM system and performance 1Q 2024 Pre-clinical trial
Slide 14: Conclusion
13 Conclusion 1• Novel AST Solution, Supported by Years of Experience and Learnings from Pheno® Launch and BD Partnership •2 Wave™ Solution Potentially Could Unlock Next Gen Technology and Improved Economic Opportunity • Growing $2B+ Market Opportunity in AST Remains a Significant Opportunity in Nee
Accelerate Diagnostics — Investor Presentation (December 2023) on 6ix